



Global Reach



Speed & Delivery



Therapeutic Knowledge



Creative Solutions

PPD Business Highlights
May 2017



PPD: Focused on Our Customers' Goals

Our Purpose:
Improve Health


Our Mission:
Help our Customers Deliver Life-Changing Therapies

Our Strategy:
Bend the Cost and Time Curve of Drug Development

2 HELPING DELIVER LIFE-CHANGING THERAPIES **PPD**

PPD's purpose and mission are to improve health by helping our customers deliver life-changing therapies. Our business goals are shaped by this philosophy and achieved by our strategy of bending the cost and time curve of drug development.

Our company is committed to being the global leader in our industry based on consistent quality and execution, exceptional customer-aligned service and constant innovation. We aim to be the premier strategic partner for the biopharmaceutical industry in addressing the difficult challenges that are affecting our industry while focusing on innovation that speeds the overall execution of clinical trials. By combining process and quality disciplines with industry-leading technology and data analytics, we bring our customers solutions that address the cost constraints of the expensive development cycle.



PPD Recapitalizes with Owners and Investors

PPD announced that its owners, affiliates of Hellman & Friedman and affiliates of The Carlyle Group (Carlyle), entered into definitive agreements that recapitalized PPD and expanded the company's ownership to include two new investors, a subsidiary of the Abu Dhabi Investment Authority (ADIA) and an affiliate of GIC, Singapore's sovereign wealth fund (GIC). GIC and ADIA had been longtime investors in Carlyle and Hellman & Friedman and are now direct investors in PPD. We have experienced significant growth during the past five years of private equity ownership, which provides a very solid foundation for success as we enter the next chapter in our company's history.

PPD Creates Dedicated Real-world Research and Market Access Unit

PPD announced the creation of a dedicated unit combining its medical affairs research operations (MARO) team and Evidera, the provider of evidence-based solutions to demonstrate the real-world effectiveness, safety and value of biopharmaceutical and biotechnology products. PPD acquired Evidera last year, uniting two best-in-class research companies to create transformative opportunities for biopharmaceutical clients.

PPD Strengthens Therapeutic Area Expertise

PPD has added two new leaders in product development, strengthening the global contract research organization's therapeutic expertise and ability to aid biopharmaceutical clients in delivering life-changing therapies to patients. Stephen Peroutka, M.D., Ph.D., has joined PPD to serve as vice president of global product development and therapeutic area head for neuroscience. Horacio Plotkin, M.D., FAAP, joined PPD as vice president of global product development in the pediatrics and rare diseases therapeutic area and also serves as medical lead for the Rare Disease and Pediatric Center of Excellence.

PPD Announces Industry-first Apprenticeship for Clinical Research Associates

PPD launched a clinical research associates (CRA) apprenticeship program targeted to military veterans and military service members with medical backgrounds who are transitioning to the civilian workforce. PPD's initiative, the first CRA apprenticeship program registered with the U.S. Department of Labor, began in North Carolina, Texas and California in the first quarter of this year.



PPD Recognized for Superior Employee Development and Business Processes

PPD has been honored for employee development and business process programs delivering service excellence for biopharmaceutical clients. Training magazine named the company for the sixth consecutive year to its Top 125 list of businesses that excel in employee learning and development. For the second year, PPD placed in the Process Excellence Network (PEX) Awards, which recognize best practices in business processes.

PPD Ranked as a Top Business Technology Innovator

PPD was named as one of the most innovative organizations using information technology at IDG's *CIO* magazine's 29th annual CIO 100 awards. PPD's technology features innovations, including utilizing wearable or mHealth technology, and Preclarus®, PPD's portfolio of solutions that provides clients transparent, real-time access to clinical trial operations and patient data to bring life-saving therapies to patients.

Best Contract Research Organization

PPD was named the best contract research organization in the *Triangle Business Journal's* 2016 Life Sciences Awards. PPD is committed to helping biopharmaceutical clients accelerate the development of life-changing medicines to improve health. PPD is among the largest life-science sector employers in North Carolina's Research Triangle region, providing services that span clinical development.

International Clinical Research Team of the Year

PPD researchers earned the *PharmaTimes* International Clinical Team of the Year honor in the 2016 competition. The award was the culmination of a demanding series of challenges, including presentations before a panel of experienced industry judges.

CIO Mike Wilkinson Recognized for Inspiring Leadership

Mike Wilkinson, Ph.D., executive vice president and chief information officer for PPD, has been named to the 2016 *PharmaVOICE* 100 list of the most inspiring people in the life sciences industry.

Copyright, 2017 by Pharmaceutical Product Development, LLC ("PPD"). All rights reserved. This presentation, including the information contained herein and commentary associated herewith ("materials"), is provided as a service of PPD. These Materials, based on publicly available information as well as the knowledge and experience of PPD's employees, have been prepared solely for informational and educational purposes and should not be relied upon for professional advice. Any further use of these Materials requires the express written consent of PPD.